Background
Methods
Renal biopsies
Cancer diagnoses
Cancer epidemiology
Patient data
Calculations
Statistics
Results
Glomerulonephritis and prevalent cancer
No. patients | Age (yrs) | Female (%) | Patients with Cancer | Prevalence (%) | Expected prevalence (%) | Risk Ratio | |
---|---|---|---|---|---|---|---|
Minimal change | 428 | 43,3 ± 19 | 46 | 19 | 4,4 | 1.9 |
2.4 (1.4–3.7)
c
|
Endocapillary | 137 | 43,4 ± 18 | 53 | 7 | 5,1 | 1.7 |
3.0 (1.2–6.2)
a
|
Focal segmental glomerulosclerosis | 408 | 49,0 ± 17 | 34 | 27 | 6,6 | 2.7 |
2.4 (1.6–3.5)
c
|
Mesangioproliferative | 1185 | 42,2 ± 17 | 36 | 36 | 3,0 | 1.7 |
1,8 (1.2–2.5)
b
|
Membranous | 741 | 52,3 ± 17 | 41 | 37 | 5,0 | 3.2 |
1.5 (1.1–2.1)
a
|
Membranoproliferative | 298 | 49,2 ± 17 | 50 | 22 | 7,4 | 2.4 |
3.1 (1.9–4.7)
c
|
Proliferative | 113 | 43,4 ± 19 | 46 | 7 | 6,2 | 2.1 |
2.9 (1.2–6.0)
a
|
Focal segmental proliferative | 507 | 47,3 ± 19 | 36 | 15 | 3,0 | 2.3 | 1,3 (0.7–2.1) |
Focal | 146 | 56,1 ± 17 | 41 | 6 | 4,1 | 3.1 | 1.3 (0.5–1.8) |
Crescentic | 610 | 58,4 ± 16 | 39 | 27 | 4,4 | 3.9 | 1.1 (0.7–1.6) |
Unclassified | 552 | 55,4 ± 18 | 41 | 82 | 14,9 | 3.0 |
4.9 (3.9–6.1)
c
|
Anti-GBMGN | 92 | 55,5 ± 22 | 53 | 1 | 1,1 | 4.4 | 0.2 (0–1.4) |
ANCA associated vasculitis | 278 | 59,1 ± 16 | 38 | 21 | 7,6 | 4.2 |
1,8 (1.1–2.5)
a
|
Lupus nephritis unspecified | 99 | 38,1 ± 17 | 77 | 1 | 1,0 | 1.5 | 0,7 (0–3.8) |
Lupus nephritis all | 422 | 36.4 ± 15 | 77 | 7 | 1.7 | 0.7 | 1.2 (0.5–2.5) |
Any | 5594 | 49.4 ± 18 | 41 | 330 | 5.5 | 3.1 |
1,8 (1.4–2.1)
c
|
Glomerulonephritis and cancer incidence
Time interval (years) | -10 to −5 | −5 to −3 | −3 to −1 | −1 to 0 | 0–1 | 1–3 | 3–5 | 5–10 | −10 to 10 | |
---|---|---|---|---|---|---|---|---|---|---|
Minimal change | Observed | 0.19 | 0.24 | 0.82 | 1.40 | 2.44 | 1.39 | 0.64 | 0.72 | 0.73 |
Expected | 0.15 | 0.23 | 0.31 | 0.41 | 0.59 | 0.64 | 0.71 | 0.84 | 0.45 | |
Risk ratio | 1.2 (0.3–3.2) | 1.0 (0.1–3.8) |
2.6 (1.1–5.4)
a
|
3.4 (1.2–7.4)
b
|
4.1 (2.0–7.6)
c
|
2.2 (1.0–4.0)
a
| 0.9 (0.2–2.3) | 0.9 (0.4–1.6) |
1.6 (1.2–2.1)
c
| |
Endocapillary | Observed | 0.15 | 0.36 | 1.09 | 1.46 | 3.32 | 0.50 | 1.51 | 0.29 | 0.72 |
Expected | 0.14 | 0.21 | 0.29 | 0.39 | 0.58 | 0.63 | 0.71 | 0.84 | 0.42 | |
Risk ratio | 1.1 (0–6.1) | 1.8 (0–9.9) |
3.8 (0.8–11.2)
a
| 3.7 (0.4–13.4) |
5.8 (1.6–14.7)
b
| 0.8 (0–4.4) | 2.1 (0.3–7.7) | 0.3 (0–1.9) |
1.7 (1.0–2.9)
a
| |
Focal segmental glomerulosclerosis | Observed | 0.35 | 0.74 | 0.86 | 1.72 | 2.08 | 1.05 | 0.92 | 2.10 | 0.96 |
Expected | 0.20 | 0.32 | 0.44 | 0.57 | 0.81 | 0.89 | 1.00 | 1.19 | 0.57 | |
Risk ratio | 1.8 (0.7–3.6) |
2.3 (0.9–5.1)
a
| 1.9 (0.8–4.0) |
3.0 (1.2–6.2)
a
|
2.5 (1.1–5.0)
a
| 1.2 (0.5–2.4) | 0.9 (0.3–2.4) |
1.8 (0.9–3.0)
p = 0.06
|
1.7 (1.3–2.2)
c
| |
Mesangio- proliferative | Observed | 0.17 | 0.38 | 0.34 | 0.76 | 1.05 | 0.83 | 0.97 | 1.14 | 0.58 |
Expected | 0.12 | 0.19 | 0.26 | 0.36 | 0.50 | 0.56 | 0.63 | 0.77 | 0.38 | |
Risk ratio | 1.4 (0.7–2.6) |
2.0 (0.9–3.9)
a
| 1.3 (0.6–2.5) |
2.1 (1.0–4.1)
a
|
2.1 (1.0–3.8)
a
| 1.5 (0.8–2.5) | 1.5 (0.9–2.5) |
1.5 (1.0–2.1)
a
|
1.5 (1.2–1.8)
c
| |
Membranous | Observed | 0.30 | 0.55 | 0.74 | 0.94 | 3.90 | 1.77 | 0.93 | 2.39 | 1.10 |
Expected | 0.22 | 0.33 | 0.47 | 0.62 | 0.91 | 0.99 | 1.10 | 1.30 | 0,65 | |
Risk ratio | 1.4 (0.7–2.5) | 1.6 (0.7–3.2) | 1.6 (0.8–2.9) | 1.5 (0.6–3.1) |
4.3 (2.8–6.3)
c
|
1.8 (1.1–2.8)
a
| 0.8 (0.4–1.6) |
1.8 (1.3–2.6)
c
|
1.7 (1.4–2.0)
c
| |
Membrano- proliferative | Observed | 0.48 | 0.34 | 0.68 | 3.04 | 3.81 | 2.24 | 1.45 | 1.05 | 1.18 |
Expected | 0.20 | 0.30 | 0.42 | 0.54 | 0.78 | 0.85 | 0.94 | 1.10 | 0.55 | |
Risk ratio |
2.4 (1.0–4.9)
a
| 1.1 (0.1–4.0) | 1.6 (0.4–4.1) |
5.6 (2.6–10.6)
c
|
4.9 (2.3–9.0)
c
|
2.6 (1.2–5.0)
b
| 1.5 (0.4–4.0) | 1.0 0.4–2.0) |
2.2 (1.6–2.8)
c
| |
Proliferative | Observed | 0.53 | 0 | 0.88 | 1.78 | 1.92 | 0 | 0 | 2.95 | 0.87 |
Expected | 0.14 | 0.22 | 0.31 | 0.41 | 0.60 | 0.66 | 0.74 | 0.88 | 0.43 | |
Risk ratio |
3.7 (0.8–10.8)
a
| 0 (0–7.6) | 2.9 (0.3–10.4) | 4.3 (0.5–15.5) | 3.2 (0.4–11.5) | 0 (0–3.2) | 0 (0–3.5) |
3.4 (1.1–7.8)
c
|
2.0 (1.1–3.4)
a
| |
Focal segmental proliferative | Observed | 0.16 | 0.20 | 0.49 | 0.79 | 1.14 | 1.29 | 1.50 | 1.76 | 0.74 |
Expected | 0.17 | 0.26 | 0.36 | 0.49 | 0.71 | 0.78 | 0.87 | 1.02 | 0.52 | |
Risk ratio | 0.9 (0.3–2.4) | 0.8 (0.1–2.8) | 1.4 (0.5–3.2) | 1.6 (0.4–4.2) | 1.6 (0.5–3.7) | 1.7 (0.8–3.0) | 1.7 (0.8–3.2) |
1.7 (1.1–2.6)
a
|
1.4 (1.1–1.8)
b
| |
Focal | Observed | 0 | 1.03 | 0.35 | 1.37 | 1.67 | 0.66 | 2.48 | 0.95 | 0.70 |
Expected | 0.29 | 0.44 | 0.61 | 0.78 | 1.14 | 1.23 | 1.34 | 1.55 | 0.75 | |
Risk ratio | 0 (0–1.8) | 2.3 (0.5–6.9) | 0.6 (0–3.3) | 1.8 (0.2–6.4) | 1.5 (0.2–5.3) | 0.5 (0–3.0) | 1.9 (0.4–5.4) | 0.6 (0.1–1.8) | 0.9 (0.5–1.6) | |
Crescentic | Observed | 0.23 | 0.49 | 0.49 | 1.31 | 1.00 | 1.88 | 2.49 | 2.28 | 0.91 |
Expected | 0.30 | 0.46 | 0.64 | 0.84 | 1.25 | 1.34 | 1.46 | 1.67 | 0.79 | |
Risk ratio | 0.8 (0.3–1.6) | 1.1 (0.4–2.3) | 0.8 (0.3–1.9) | 1.6 (0.7–3.1) | 0.8 (0.3–1.9) | 1.4 (0.8–2.4) | 1.7 (0.9–2.9) | 1.4 (0.8–2.1) | 1.2 (0.9–1.4) | |
Unclassified | Observed | 0.58 | 1.09 | 1.18 | 7.43 | 6.71 | 2.41 | 1.44 | 2.10 | 1.94 |
Expected | 0.28 | 0.43 | 0.59 | 0.77 | 1.14 | 1.22 | 1.33 | 1.52 | 0.74 | |
Risk ratio |
2.1 (1.2–3.3)
a
|
2.5 (1.3–4.4)
b
|
2.0 (1.1–3.4)
a
|
9.7 (6.9–13.1)
c
|
5,9 (4.0–8.3)
c
|
2,0 (1.2–3.1)
b
| 1.1 (0.4–2.2) | 1.4 (0.8–2.3) |
2.6 (2.2–3.1)
c
| |
Anti-GBM GN | Observed | 0.00 | 0.54 | 0.00 | 0.00 | 1.22 | 3.11 | 0.00 | 2.93 | 0.6 |
Expected | 0.31 | 0.46 | 0.62 | 0.80 | 1.20 | 1.26 | 1.34 | 1.49 | 0.7 | |
Risk ratio | 0 (0–2.6) | 1.2 (0–6.6) | 0 (0–3.3) | 0 (0–5.1) | 1.0 (0–5.7) | 2.5 (0.5–7.2) | 0 (0–2.8) | 2.0 (0.4–5.8) | 0.8 (0.4–1.6) | |
ANCA-associated vasculitis | Observed | 0.50 | 0.54 | 1.08 | 1.80 | 2.96 | 1.90 | 2.43 | 2.48 | 1.37 |
Expected | 0.29 | 0.45 | 0.62 | 0.84 | 1.27 | 1.36 | 1.48 | 1.69 | 0.84 | |
Risk ratio | 1.72 (0.7–3.5) | 1.2 (0.2–3.5) | 1.7 (0.6–3.8) | 2.1 (0.7–5.0) | 2.3 (0.9–4.8) | 1.4 (0.6–2.9) | 1.6 (0.7–3.1) | 1.5 (0.8–2.5) |
1.6 (1.2–2.1)
c
| |
Lupus nephritis unspecified | Observed | 0 | 0 | 0.51 | 0 | 1.14 | 1.71 | 2.40 | 0.75 | 0.60 |
Expected | 0.10 | 0.15 | 0.21 | 0.28 | 0.40 | 0.44 | 0.49 | 0.59 | 0.31 | |
Risk ratio | 0 (0–7.9) | 0 (0–12.7) | 2.4 (0.1–13.6) | 0 (0–13.3) | 2.9 (0.1–15.9) | 3.9 (0.5–14.0) | 4.9 (0.6–17.6) | 1.3 (0.3–3.7) | 1.9 (0.9–3.7) | |
Lupus nephritis all | Observed | 0.10 | 0.24 | 0.24 | 0.24 | 0.78 | 0.83 | 0.56 | 0.89 | 0.42 |
Expected | 0.09 | 0.14 | 0.19 | 0.25 | 0.34 | 0.38 | 0.43 | 0.52 | 0.26 | |
Risk ratio | 1.1 (0.1–3.9) | 1.7 (0.2–6.3) | 1.2 (0.1–4.4) | 0.9 (0–5.3) | 2.3 (0.5–6.8) | 2.2 (0.7–5.2) | 1.3 (0.2–4.7) | 1.7 (0.9–3.0) |
1.6 (1.1–2.3)
a
| |
Any | Observed | 0.28 | 0.49 | 0.66 | 1.83 | 2.51 | 1.48 | 1.34 | 1.71 | 0.96 |
Expected | 0.20 | 0.31 | 0.43 | 0.57 | 0.83 | 0.90 | 1.00 | 1.17 | 0.58 | |
Risk ratio |
1.4 (1.1–1.7)
b
|
1.6 (1.2–2.1)
b
|
1.5 (1.2–1.9)
c
|
3.2 (2.6–3.9)
c
|
3.0 (2.5–3.6)
c
|
1.6 (1.4–2.0)
c
|
1.3 (1.1–1.7)
a
|
1.5 (1.3–1.7)
c
|
1.7 (1.5–1.8)
c
|
Relationship of cancer type to incidence
Time interval (years) | −10 to −5 | −5 to −3 | −3 to −1 | −1 to 0 | 0–1 | 1–3 | 3–5 | 5–10 | −10 to 10 | |
---|---|---|---|---|---|---|---|---|---|---|
Colorectal | Observed | 0.03 | 0.06 | 0.05 | 0.07 | 0.26 | 0.06 | 0.14 | 0.17 | 0.08 |
Expected | 0.05 | 0.09 | 0.12 | 0.17 | 0.22 | 0.24 | 0.27 | 0.33 | 0.16 | |
Risk ratio | 0.5 (0,2–1.0) | 0.7 (0.3–1.5) |
0.4 (0.2–0.9)
b
| 0.4 (0.1–1.1) | 1.2 (0.6–2.1) |
0.2 (0.1–0.5)
d
| 0.5 (0.2–1.0) |
0.5 (0.3–0.9)
c
|
0.5 (0.4–0.6)
d
| |
Lung | Observed | 0.00 | 0.03 | 0.04 | 0.20 | 0.32 | 0.26 | 0.17 | 0.23 | 0.10 |
Expected | 0.01 | 0.01 | 0.02 | 0.06 | 0.12 | 0.13 | 0.14 | 0.16 | 0.06 | |
Risk ratio | 0.7 (0–3.9) | 2.8 (0.6–8.2) | 1.8 (0.5–4.6) |
3.1 (1.6–5.6)
c
|
2.7 (1.5–4.4)
d
|
2.0 (1.2–3.1)
c
| 1.2 (0.6–2.3) | 1.4 (0.9–2.1) |
1.6 (1.3–2.0)
d
| |
Melanoma | Observed | 0.01 | 0.03 | 0.01 | 0.04 | 0.02 | 0.07 | 0.07 | 0.08 | 0.03 |
Expected | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.03 | |
Risk ratio | 0.7 (0.2–2.1) | 1.3 (0.3–3.7) | 0.3 (0–1.8) | 1.1 (0.1–3.9) | 0.6 (0–3.4) | 2.3 (0.8–5.0) | 2.1 (0.6–5.5) | 2.1 (0.9–4.4) | 1.2 (0.8–1.7) | |
Breasta | Observed | 0.13 | 0.11 | 0.11 | 0.22 | 0.19 | 0.12 | 0.03 | 0.28 | 0.15 |
Expected | 0.09 | 0.12 | 0.17 | 0.18 | 0.18 | 0.19 | 0.20 | 0.22 | 0.15 | |
Risk ratio | 1.4 (0.8–2.3) | 0.9 (0.3–2.0) | 0.6 (0.2–1.5) | 1.2 (0.4–2.8) | 1.0 (0.3–2.7) | 0.6 (0.2–1.6) |
0.1 (0–0.8)
b
| 1.2 (0.7–2.0) | 1.0 (0.7–1.3) | |
Gynaecologica | Observed | 0.02 | 0.02 | 0.09 | 0.13 | 0.05 | 0.03 | 0.09 | 0.05 | 0.05 |
Expected | 0.04 | 0.05 | 0.06 | 0.07 | 0.09 | 0.09 | 0.10 | 0.11 | 0.07 | |
Risk ratio | 0.4 (0.1–1.5) | 0.4 (0–2.5) | 1.4 (0.4–3.6) | 1.7 (0.4–5.1) | 0.5 (0–3.0) | 0.4 (0–2.1) | 1.0 (0.2–2.8) | 0.5 (0.1–1.2) | 0.7 (0.4–1.2) | |
Prostatea | Observed | 0.04 | 0.08 | 0.12 | 0.49 | 0.74 | 0.22 | 0.20 | 0.27 | 0.19 |
Expected | 0.04 | 0.09 | 0.15 | 0.17 | 0.18 | 0.20 | 0.22 | 0.27 | 0.14 | |
Risk ratio | 1.1 (0.5–2.3) | 0.8 (0.3–1.9) | 0.8 (0.4–1.6) |
2.9 (1.7–4.8)
d
|
4.2 (2.6–6.5)
d
| 1.1 (0.5–2.0) | 0.9 (0.4–1.9) | 1.0 (0.6–1.6) |
1.3 (1.1–1.7)
d
| |
Renal | Observed | 0.01 | 0.02 | 0.03 | 0.29 | 0.16 | 0.03 | 0 | 0.05 | 0.05 |
Expected | 0.004 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | |
Risk ratio | 2.0 (0.2–7.1) | 2.9 (0.3–10.4) | 3.0 (0.6–8.6) |
21.4 (12.2–34.8)
d
|
9.2 (4.0–18.2)
d
| 1.8 (0.4–5.1) | 0 (0–2.4) |
2.3 (0.9–4.7)
b
|
4.1 (2.9–3.5)
d
| |
Bladder | Observed | 0.01 | 0.02 | 0.03 | 0 | 0.02 | 0.05 | 0.05 | 0.09 | 0.03 |
Expected | 0.02 | 0.03 | 0.04 | 0.05 | 0.06 | 0.07 | 0.08 | 0.09 | 0.05 | |
Risk ratio |
0
.2
(0–0.9
)
b
| 0.6 (0.1–2.0) | 0.7 (0.1–1.9) | 0 (0–1.3) | 0.3 (0–1.8) | 0.7 (0.1–2.1) | 0.6 (0.1–1.8) | 0.9 (0.4–1.9) |
0.5 (0.3–0.8)
c
| |
Hodgkin lymphoma | Observed | 0 | 0.01 | 0.01 | 0 | 0.02 | 0 | 0.00 | 0.01 | 0.004 |
Expected | 0.002 | 0.002 | 0.002 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 | |
Risk ratio | 0 (0–6.7) | 3.9 (0.1–21.7) | 3.7 (0.1–20.8) | 0 (0–25.2) | 6.3 (0.2–34.9) | 0 (0–13.9) | 0 (0–15.8) | 3.2 (0.1–17.9) | 1.6 (0.4–4.2) | |
Non-Hodgkin Lymphoma | Observed | 0.01 | 0.02 | 0.03 | 0.16 | 0.17 | 0.03 | 0.06 | 0.06 | 0.04 |
Expected | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | |
Risk ratio | 1.4 (0.3–4.2) | 1.5 (0.2–5.5) | 1.8 (0.4–5.3) |
8.1 (3.7–15.4)
d
|
7.3 (3.1–14.3)
d
| 1.1 (0.1–4.0) | 2.3 (0.6–5.9) | 1.9 (0.7–4.1) |
2.5 (1.8–3.5)
d
| |
Myeloma | Observed | 0.004 | 0.01 | 0.02 | 0.23 | 0.44 | 0.02 | 0 | 0.02 | 0.05 |
Expected | 0.001 | 0.003 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Risk ratio | 3.1 (0.1–17.4) | 3.0 (0.1–16.8) | 3.6 (0.4–12.9) |
32.6 (17.3–55.7)
d
|
49.4 (31.0–74.8)
d
| 2.2 (0.3–7.8) | 0 (0–4.4) | 1.6 (0.3–4.8) |
8.6 (6.3–11.6)
d
| |
Leukaemia | Observed | 0.01 | 0.03 | 0.06 | 0.09 | 0.17 | 0.03 | 0.05 | 0.06 | 0.04 |
Expected | 0.01 | 0.02 | 0.02 | 0.03 | 0.04 | 0.05 | 0.05 | 0.06 | 0.03 | |
Risk ratio | 0.8 (0.1–2.8) | 1.7 (0.4–5.0) |
2.9 (1.2–6.0)
b
|
3.1 (1.0–7.3)
b
|
3.9 (1.7–7.7)
c
| 0.7 (0.1–2.5) | 1.0 (0.2–2.8) | 0.9 (0.4–1.9) |
1.5 (1.0–2.0)
b
| |
Skin (non-melanoma) | Observed | 0.08 | 0.14 | 0.22 | 0.21 | 0.14 | 0.54 | 0.64 | 0.74 | 0.27 |
Expected | 0.01 | 0.02 | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 | 0.07 | 0.03 | |
Risk ratio |
7.8 (4.9–11.7)
c
|
7.4 (4.2–12.0)
d
|
8.6 (5.5–12.6)
d
|
6.4 (3.3–11.1)
d
|
3.6 (1.5–7.5)
c
|
12.1 (8.7–16.3)
d
|
12.1 (8.5–16.7)
d
|
10.9 (8.5–13.8)
d
|
8.7 (7.6–9.9)
d
| |
Unclassified | Observed | 0.04 | 0.05 | 0.07 | 0.22 | 0.53 | 0.33 | 0.25 | 0.43 | 0.17 |
Expected | 0.04 | 0.05 | 0.07 | 0.11 | 0.19 | 0.20 | 0.22 | 0.25 | 0.12 | |
Risk ratio | 1.1 (0.6–2.0) | 1.1 (0.4–2.4) | 1.0 (0.4–2.0) |
1.9 (1.0–3.3)
b
|
2.8 (1.9–4.1)
d
|
1.6 (1.1–2.4)
b
| 1.1 (0.7–1.8) |
1.7 (1.2–2.3)
c
|
1.5 (1.2–1.7)
d
| |
Any not skin | Observed | 0.20 | 0.35 | 0.46 | 1.63 | 2.37 | 0.99 | 0.77 | 1.06 | 0.71 |
Expected | 0.19 | 0.30 | 0.41 | 0.55 | 0.80 | 0.86 | 0.95 | 1.10 | 0.55 | |
Risk ratio | 1.0 (0.8–1.3) | 1.2 (0.8–1.6) | 1.1 (0.8–1.5) |
2.9 (2.6–3.4)
d
|
3.0 (2.5–3.6)
d
| 1.1 (0.9–1.4) | 0.8 (0.6–1.1) | 1.0 (0.8–1.1) |
1.3 (1.2–1.4)
d
|
Renal Diagnosis | Stomach | Pancreas | Liver | Sarcoma | Brain | Thymus |
---|---|---|---|---|---|---|
Minimal Change | 0a | 0a | 1 | 0a | 0a | |
FSGS | 2a | 2a | 1a | 0a | 0a | |
Mesangioproliferative | 4 | 2 | 2 | 0a | ||
Membranous | 1a | 2a | 1a | 1a | 1a | |
Membranoproliferative | 0a | 1a | 1 | |||
Focal segmental proliferative | 3 | 1 | ||||
Crescentic | 1a | 1a | 0a | |||
Unclassified | 4 | 2 | ||||
ANCA vasculitis | 2 |
Relationship of cancer incidence to Nephrological diagnosis
Relationship of specific Glomerulonephritis diagnoses with cancer diagnosis
Renal Diagnosis | Number | Lung | Melanoma | Breast | Gynaecologic | Prostate | Renal | Bladder | Non-Hodgkin | Myeloma | Leukaemia | Unclassified | Skin | Typical cancers in the literature |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Minimal change | 27 | 11 | 6 | 13 | 10 | 7 | 41 | Renal, lung, colorectal, thymoma, Hodgkin’s | ||||||
Endocapillary | 6 | 37 | 11 | 24 | 14 | 15 | ||||||||
FSGS | 28 | 21 | 10 | 5 | 6 | 21 | 31 | Renal, thymoma | ||||||
Mesangio-proliferative | 53 | 12 | 9 | 12 | 21 | 45 | Renal, lung, unclassified | |||||||
Membranous | 51 | 17 | 6 | 10 | 5 | 21 | 36 | Renal, gastric, prostate, lung, unclassified | ||||||
Membrano-proliferative | 33 | 12 | 20 | 9 | 10 | 8 | 37 | Renal, lung, leukaemia, unclassified | ||||||
Proliferative | 9 | 6 | 7 | 8 | 10 | 24 | 45 | |||||||
Focal segmental proliferative | 29 | 9 | 23 | 11 | 51 | |||||||||
ANCA vasculitis | 26 | 6 | 10 | 5 | 11 | 7 | 61 | Skin, leukaemia, bladder | ||||||
Lupus (all) | 17 | 9 | 11 | 21 | 58 | Hodgkin, non-Hodgkin, myeloma, lung, leukaemia | ||||||||
Unclassified | 92 | 5 | 25 | 9 | 23 | 16 | 17 |
Cancer Diagnosis | Number | MCD | End | FSGS | MesPGN | MN | MPGN | FSPGN | Focal | NCGN | Unclassified | ANCAV | Typical GN in the literature [4] |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lung | 37 | 8 | 6 | 16 | 17 | 23 | 11 | 6 | MN, MCD, MPGN, MesPGN, FSGS, NCGN | ||||
Prostate | 33 | 16 | 20 | 28 | 15 | 8 | MCD, NCGN | ||||||
Renal | 30 | 16 | 78 | NCGN, MesPGN, MCD, FSGS, MPGN | |||||||||
Non-Hodgkin | 22 | 15 | 30 | 36 | 6 | MN, MCD, MPGN, FSGS, NCGN | |||||||
Myeloma | 37 | 7 | 5 | 17 | 8 | 55 | |||||||
Leukemia | 15 | 16 | 23 | 10 | 10 | 22 | 19 | MN, MCD, MPGN, FSGS, NCGN | |||||
Skin (non-melanoma) | 152 | 7 | 6 | 16 | 12 | 8 | 10 | 12 | 11 | 10 | MN | ||
Unclassified | 56 | 11 | 20 | 19 | 5 | 6 | 26 |
Renal Diagnosis | Number | Colon | Lung | Melanoma | Breasta | Gynaecologica | Prostatea | Renal | Bladder | Hodgkin | Non-Hodgkin | Myeloma | Leukemia | Unclassified | Skin | Any | Any no skin |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
A. 15–44 years | |||||||||||||||||
Total cancer cases | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 4 | 0 | 8 | 3 | 20 | 17 | |
Minimal change | 238 | 0.4 | 0.4 | 0.4 | 1.3 | 1.3 | |||||||||||
Endocapillary | 85 | 1.3 | 1.3 | 1.3 | |||||||||||||
FSGS | 169 | 0.7 | 0.7 | 0.7 | |||||||||||||
Mesangioproliferative | 676 | 0.2 | 0.3 | 0.5 | 0.5 | ||||||||||||
Membranous | 253 | 0.7 | 0.4 | 0.9 | 0.4 | ||||||||||||
Membranoproliferative | 123 | 1.8 | 0.9 | 2.7 | 1.8 | ||||||||||||
Proliferative | 62 | ||||||||||||||||
Focal segmental proliferative | 232 | 0.5 | 0.5 | 0.5 | |||||||||||||
Focal | 38 | ||||||||||||||||
Crescentic | 110 | 1.0 | 1.0 | ||||||||||||||
Unclassified | 147 | 0.7 | 1.5 | 2.2 | 2.2 | ||||||||||||
Anti-GBM GN | 28 | 3.8 | 3.8 | 3.8 | |||||||||||||
ANCA-associated | 51 | ||||||||||||||||
Lupus unspecified | 72 | 1.6 | 1.5 | 1.5 | |||||||||||||
B. 45–64 years | |||||||||||||||||
Total cancer cases | 7 | 16 | 2 | 2 | 0 | 11 | 7 | 1 | 0 | 3 | 11 | 4 | 24 | 21 | 108 | 87 | |
Minimal change | 119 | 1.5 | 1.8 | 2.7 | 1.8 | 7.3 | 5.5 | ||||||||||
Endocapillary | 26 | 4.9 | 4.3 | 9.8 | 9.8 | ||||||||||||
FSGS | 162 | 1.4 | 0.7 | 0.9 | 0.7 | 1.4 | 4.9 | 3.5 | |||||||||
Mesangioproliferative | 367 | 0.3 | 0.6 | 0.3 | 0.9 | 1.6 | 3.8 | 2.2 | |||||||||
Membranous | 293 | 0.8 | 1.9 | 0.4 | 1.0 | 1.6 | 0.4 | 1.1 | 0.8 | 0.4 | 7.3 | 6.9 | |||||
Membranoproliferative | 112 | 2.1 | 1.0 | 1.1 | 1.1 | 3.2 | 8.6 | 5.4 | |||||||||
Proliferative | 32 | 3.4 | 3.7 | 7.4 | 7.4 | ||||||||||||
Focal segmental proliferative | 166 | 0.7 | 1.9 | 0.7 | 2.0 | 4.7 | 2.7 | ||||||||||
Focal | 56 | 2.2 | 2.2 | 2.2 | 2.2 | ||||||||||||
Crescentic | 252 | 0.5 | 1.0 | 0.6 | 2.0 | 0.5 | 3.9 | 3.4 | |||||||||
Unclassified | 203 | 0.6 | 1.2 | 0.8 | 3.0 | 0.6 | 4.3 | 4.3 | 1.2 | 15.8 | 14.6 | ||||||
Anti-GBMGN | 24 | 8.3 | 5.2 | 5.2 | |||||||||||||
ANCA-associated | 115 | 1.0 | 1.4 | 0.9 | 1.0 | 2.0 | 5.9 | 3.9 | |||||||||
Lupus unspecified | 18 | 7.0 | 7.0 | 7.0 | |||||||||||||
C: > 64 years | |||||||||||||||||
Total cancer cases | 10 | 19 | 4 | 4 | 2 | 20 | 3 | 3 | 0 | 7 | 9 | 6 | 22 | 25 | 129 | 105 | |
Minimal change | 71 | 3.4 | 1.7 | 2.9 | 2.9 | 1.7 | 1.7 | 5.1 | 16.9 | 11.8 | |||||||
Endocapillary | 26 | 6.7 | 5.9 | 0.0 | 11.8 | 11.8 | |||||||||||
FSGS | 77 | 4.9 | 1.6 | 1.7 | 4.9 | 3.2 | 16.2 | 13.0 | |||||||||
Mesangioproliferative | 142 | 2.0 | 2.2 | 3.0 | 3.9 | 3.0 | 12.8 | 9.9 | |||||||||
Membranous | 195 | 1.4 | 4.1 | 0.7 | 1.5 | 3.9 | 0.7 | 0.7 | 4.8 | 2.8 | 18.0 | 15.2 | |||||
Membranoproliferative | 63 | 2.5 | 2.5 | 7.4 | 0.0 | 7.4 | 19.6 | 12.3 | |||||||||
Proliferative | 19 | 0.0 | 0.0 | 0.0 | 0.0 | ||||||||||||
Focal segmental proliferative | 109 | 1.3 | 1.3 | 2.3 | 4.6 | 1.3 | 0.0 | 9.2 | 9.2 | ||||||||
Focal | 52 | 3.3 | 3.3 | 6.5 | 3.3 | ||||||||||||
Crescentic | 248 | 0.7 | 1.4 | 0.7 | 1.0 | 0.7 | 0.7 | 0.7 | 0.7 | 2.7 | 8.2 | 6.1 | |||||
Unclassified | 202 | 1.6 | 0.8 | 1.1 | 2.8 | 2.3 | 0.8 | 2.3 | 4.7 | 0.8 | 2.3 | 2.3 | 20.3 | 17.9 | |||
Anti-GBMGN | 40 | 9.8 | 9.8 | 9.8 | |||||||||||||
ANCA-associated | 112 | 2.7 | 5.3 | 1.3 | 1.3 | 0.0 | 2.7 | 13.4 | 10.7 | ||||||||
Lupus unspecified | 9 | 24.3 | 0.0 | 24.3 | 24.3 |